← Evidence map

ArticleCureus2026

Comparative Evaluation of Serum Peroxiredoxin 2 (PRDX2), Serum Peroxiredoxin 4 (PRDX4), and Plasma Methylated Septin 9 (mSEPT9) Levels Against Conventional Biomarkers for Early Detection of Colorectal Cancer: A Study Protocol.

Chetan K Kellellu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Comparative Evaluation of Serum Peroxiredoxin 2 (PRDX2), Serum Peroxiredoxin 4 (PRDX4), and Plasma Methylated Septin 9 (mSEPT9) Levels Against Conventional Biomarkers for Early Detection of Colorectal Cancer: A Study Protocol. | OpenQuestion